U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H17N3S
Molecular Weight 211.327
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRAMIPEXOLE

SMILES

CCCN[C@H]1CCC2=C(C1)SC(N)=N2

InChI

InChIKey=FASDKYOPVNHBLU-ZETCQYMHSA-N
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf

Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. Pramipexole is used for the treatment of signs and symptoms of idiopathic Parkinson's disease.

CNS Activity

Originator

Approval Year

1997
189
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 1.5 nM [EC50]
Agonist
2752
 27.0 nM [EC50]
Agonist
2752
 15.0 nM [EC50]
Inhibitor
8504
 4.81 µM [IC50]
Inhibitor
8504
 5.37 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

1997
Primary
Approved
8583
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.268 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.29 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20110012
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Disc. AE: Hallucination, Hypotension...
AEs leading to
discontinuation/dose reduction:
Hallucination (1.3%)
Hypotension (0.5%)
Peripheral edema (0.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Disc. AE: Hallucinations, Sleepiness...
AEs leading to
discontinuation/dose reduction:
Hallucinations (4.3%)
Sleepiness (3%)
Dizziness (2.5%)
Memory loss (1.2%)
Paranoia (0.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
DLT: Drowsiness, Muscle spasms...
Dose limiting toxicities:
Drowsiness (3.6%)
Muscle spasms (1.8%)
Insomnia (1.8%)
Vertigo (1.8%)
Ankle swelling (1.8%)
Hallucination (3.6%)
Nausea (1.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Disc. AE: Hallucination, Peripheral edema...
AEs leading to
discontinuation/dose reduction:
Hallucination (1%)
Peripheral edema (0.8%)
Abdominal pain upper (0.6%)
Myocardial infarction (0.6%)
Nausea (0.6%)
Pneumonia (0.6%)
Vomiting (0.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
AEs

AEs

AESignificanceDosePopulation
Hypotension 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Peripheral edema 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Hallucination 1.3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Paranoia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Memory loss 1.2%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Dizziness 2.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Sleepiness 3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Hallucinations 4.3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9305331
Ankle swelling 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Insomnia 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Muscle spasms 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Nausea 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Vertigo 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Drowsiness 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Hallucination 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9214527
Abdominal pain upper 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Myocardial infarction 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Nausea 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Pneumonia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Vomiting 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Peripheral edema 0.8%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Hallucination 1%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24834511
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8356
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8356
ChemicalBook
CB0486178
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0486178
eMolecules
6843675
https://www.emolecules.com/cgi-bin/more?vid=6843675
MolPort
MolPort-003-849-957
https://www.molport.com/shop/molecule-link/MolPort-003-849-957
Selleck Chemicals
Pramipexole-Mirapex
http://www.selleckchem.com/products/Pramipexole-Mirapex.html
ZINC
ZINC000003781664
http://zinc15.docking.org/substances/ZINC000003781664
PubMed

PubMed

TitleDatePubMed
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
1999 Nov 26
Pramipexole-induced somnolence and episodes of daytime sleep.
2000 Jul
Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
2001
Economic and health-related quality of life considerations of new therapies in Parkinson's disease.
2001
Sleep disorders in patients with Parkinson's disease: epidemiology and management.
2001
Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.
2001 Jul
Pramipexole augmentation in panic with agoraphobia.
2001 Mar
Daytime sleepiness and other sleep disorders in Parkinson's disease.
2001 Oct 23
Choosing the right dopamine agonist for patients with Parkinson's disease.
2002
'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?
2002
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
2002 Apr 3
Pramipexole for depression.
2002 Feb
Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma.
2002 Feb 15
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.
2002 Jan 23-30
[Rhabdomyolysis as a complication of Parkinson's disease].
2002 Jan-Feb
Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease.
2002 Jan-Feb
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
2002 Jun
[Multiple latency test in a patient with episodes of sleep induced by pergolide].
2002 Jun 16-30
Sleep attacks in patients taking dopamine agonists: review.
2002 Jun 22
A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole.
2002 May
Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
2002 Oct-Dec
Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
2003
Pramipexole in comparison to l-dopa: a neuropsychological study.
2003 Apr
Piribedil-induced sleep attacks in Parkinson's disease.
2003 Feb
Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
2003 Feb
Slowing Parkinson's disease progression: recent dopamine agonist trials.
2003 Feb 11
Efficacy, safety and cost of new drugs acting on the central nervous system.
2003 May
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
2003 May
Patents

Patents

JP2006505569A
69
JP2007514770A
77
JP2011526251A
112
JP2012500800A
9
JPH03170425A
3

Sample Use Guides

In Vivo Use Guide
Dosages should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days.
Route of Administration: Oral
In Vitro Use Guide
Pramipexole suppressed H2O2-induced ARPE-19 cell death in vitro at concentrations of 10(-6) M or higher.
Name Type Language
SUD-919CL2Y
Preferred Name English
PRAMIPEXOLE
INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
U-98528E
Code English
SUD919CL2Y
Code English
PRAMIPEXOLE [USAN]
Common Name English
Pramipexole [WHO-DD]
Common Name English
NSC-760426
Code English
pramipexole [INN]
Common Name English
CTC-501
Code English
PRAMIPEXOLE [VANDF]
Common Name English
PRAMIPEXOLE [MI]
Common Name English
PRAMIPEXOL
Common Name English
Classification Tree Code System Code
WHO-VATC QN04BC05
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
LIVERTOX NBK547968
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
NDF-RT N0000000117
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
FDA ORPHAN DRUG 252007
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
NCI_THESAURUS C265
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
WHO-ATC N04BC05
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
NDF-RT N0000175768
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
Code System Code Type Description
SMS_ID
100000085495
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
PUBCHEM
119570
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
NSC
760426
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
DRUG BANK
DB00413
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
CAS
104632-26-0
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
WIKIPEDIA
PRAMIPEXOLE
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
DRUG CENTRAL
2233
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
DAILYMED
83619PEU5T
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
NCI_THESAURUS
C66456
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
USAN
HH-63
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
RXCUI
746741
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY RxNorm
LACTMED
Pramipexole
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
EPA CompTox
DTXSID6023496
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
IUPHAR
953
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
FDA UNII
83619PEU5T
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
INN
6227
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
HSDB
8253
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
CHEBI
8356
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
MESH
C061333
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
MERCK INDEX
m9095
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY Merck Index
EVMPD
SUB09990MIG
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
ChEMBL
CHEMBL301265
Created by admin on Mon Mar 31 18:07:12 GMT 2025 , Edited by admin on Mon Mar 31 18:07:12 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of PRAMIPEXOLE
SALT/SOLVATE (PARENT)
Structure of PRAMIPEXOLE DIHYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966